设为首页 |  加入收藏
首页期刊介绍编委会投稿须知通知公告刊登文章继续教育园地协办单位联系我们广告合作
公告栏:
氟喹诺酮类抗菌药物在儿童应用中的专家共识
作者: 
单位:
关键词: 
中图分类号:R969.3
文献标志码:
出版年,卷(期):页码:2018,28(1):1-10,
收稿日期:
摘要:
基金项目:
作者简介:
通讯作者:
参考文献:
[1] Albertson T E,Dean N C,El Solh A A,et al. Fluoroquinolones in the management of community-acquired pneumonia[J]. Int J Clin Pract,2010,64(3):378-388.
[2] Hsueh P R,Lau Y J,Ko W C,et al. Consensus statement on the role of fluoroquinolones in the management of urinary tract infections[J]. J Microbiol Immunol Infect, 2011,44(2):79-82.
[3] Patel K,Goldman J L.Safety concerns surrounding quinolone use in children[J]. J Clin Pharmacol, 2016,56(9):1060-1075.
[4] Yabe K,Satoh H,Ishii Y,et al. Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin,a quinolone antimicrobial agent[J]. Vet Pathol,2004,41(6):673-681.
[5] Committee on Infectious Diseases. The use of systemic fluoroquinolones[J]. Pediatrics,2006,118(3):1287-1292.
[6] Hambel B,Hullmann R,Schmidt H,et al. Ciprofloxacin in pediatrics:worldwild clinical experience based on compassionate use-safety report[J]. Pediatr Infect Dis J,1997,16(1):127-129.
[7] Bacci C,Galli L,de Martino M,et al. Fluoroquinolones in children:update of the literature[J]. J Chemotherapy,2015,27(5):257-265.
[8] Goldman J A,Kearns G L,Pharm D. Fluoroquinolone use in paediatrics:focus on safety and place in therapy[P]. 18th Expert Committee on the Selection and Use of Essential Medicines,2011:1-13.
[9] Gendrel D,Chalumeau M,Moulin F,et al. Fluoroquinolones in paediatrics:a risk for the patient or for the community[J]. Lancet Infect Dis,2003,3(9):537-546.
[10] Chien S,Wells T G,Blumer J L,et al. Levo oxacin pharmacokinetics in children[J]. J Clin Pharmacol,2005,45(2):153-160.
[11] Li F,Nandy P,Chien S,et al. Pharmacometrics-based dose selection of levo oxacin as a treatment for postexposure inhalational anthrax in children[J]. Antimicrob Agents Chemother, 2010,54(1):375-379.
[12] 国家食品药品监督管理总局.总局关于修订全身用氟喹诺酮类药品说明书的公告:2017年第79号[S].2017.
[13] Machida M,Kusajima H,Maeda A,et al. A toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals[J]. Toxicol Appl Pharmacol,1990,105(3):403-412.
[14] von Keutz E,Rühl-Fehlert C,Drommer W,et al. Effects of cipro oxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period[J]. Arch Toxicol,2004,78(7):418-424
[15] Sansone J M,Wilsman N J,Leiferman E M,et al. The effect of uoroquinolone antibiotics on growing cartilage in the lamb model[J]. J Pediatr Orthop,2009,29(2):189-195
[16] US Food and Drug Administration,Division of Special Pathogen and Immunologic Drug Products. Summary of clinical review of studies submitted in a response to a pediatric written request:cipro oxacin[OL].(2016-01-13)[2017-07-11]. www. fda. gov/downloads/drugs/developmentapprov alprocess/developmentresour ces/ucm 447421. pdf.
[17] Noel G J,Bradley J S,Kauffman R E,et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders[J]. Pediatr Infect Dis J,2007,26(10):879-891.
[18] Bradley J S,Kauffman R E,Balis D A,et al. Assessment of musculoskeletal toxicity 5 years after therapy with levo oxacin[J]. Pediatrics,2014,134(1):e146-e153.
[19] Kaguelidou F,Turner M A,Choonara I,et al. Ciprofloxacin use in neonates:a systematic review of the literature[J]. Pediatr Infect Dis J,2011,30(2):29-37.
[20] 金福.儿童必须规范应用喹诺酮类药[J].药学与临床,2009,12(6):796-798.
[21] Chalumeau M,Tonnelier S,D'Athis P,et al. Fluoroquinolone safety in pediatric patients:a prospective,multicenter,comparative cohortstudy in France[J]. Pediatrics,2003,111(6 Pt 1):e714-e719.
[22] Sendzik J,Lode H, Stahlmann R. Quinolone-induced arthropathy:an update focusing on new mechanistic and clinical data[J]. Int J Antimicrob Agents,2009,33(3):194-200.
[23] 国家药典委员会.中华人民共和国药典临床用药须知[M].北京:人民卫生出版社,2005:559.
[24] 《抗菌药物临床应用指导原则》修订工作组.抗菌药物临床应用指导原则(2015年版)[M].北京:人民卫生出版社,2015:57.
[25] 中华儿科杂志编辑委员会.关于喹诺酮类药在儿童的应用[J]. 中华儿科杂志,1996,34(5):358-359.
[26] 胡亚美,江载芳.诸福棠实用儿科学[M].第7版.北京:人民卫生出版社,2010:874-892.
[27] James E F,Reynolds. MARTINDALE the extra pharmacopoeia[M]. London:Royal Pharmaceutical Society,2000:129-298.
[28] Micromedex (169)[DB/OL]. Truven Health Analytic Inc. 2017[2017-7-11]. http://www.micromedexsolutions.com/home/dispatch.
[29] Paediatric Formulary Committee.BNF for Children 2014-2015(BNFC)[M].Britain:Pharmaceutical Press,2014.
[30] Wright J G,Quinn C P,Shadomy S,et al. Use of anthrax vaccine in the United States:recommendations of the Advisory Committee on Immunization Practices (ACIP),2009[J]. MMWR Recomm Rep,2010,59(RR-6):1-30.
[31] Gupta K,Hooton T M,Naber K G,et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women:a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases[J]. Clin Infect Dis,2011,52(5):e103-e120.
[32] Centers for Disease Control and Prevention (CDC):Resources for clinicians-recommended antibiotic treatment for plague. Centers for Disease Control and Prevention(CDC)[EB/OL].(2015-06-28)[2017-07-11].https://www.cdc.g.
[33] Treggiari M M,Retsch-Bogart G,Mayer-Hamblett N,et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis[J]. Arch Pediatr Adolesc Med,2011,165(9):847-856.
[34] Mogayzel P J,Naureckas E T,Robinson K A,et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection[J]. Ann Am Thorac Soc,2014,11(10):1640-1650.
[35] Freifeld A G,Bow E J,Sepkowitz K A.Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer:2010 update by the infectious diseases society of america[J]. Clin Infect Dis, 2011,52(4):e56-e93.
[36] 中华医学会血液学分会,中国医师协会血液科医师分会.中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2016年版)[J]. 中华血液学杂志,2016,37(5):353-359.
[37] Lehrnbecher T,Robinson P,Fisher B,et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients:2017 update[J]. J Clin Oncol, 2017,35(18):2082-2094.
[38] Castagnola E,Moroni C,Bandettini R,et al. Ciproloxacin prophylaxis in children with acute leukemia in an era of increasing antibiotic resistance[J]. Pediatr Infect Dis J,2013,32(5):581.
[39] Bradley J S,Byington C L,Shah S S,et al. The management of community-acquired pneumonia in infants and children older than 3 months of age:clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America[J]. Clin Infect Dis,2011,53(7):e25-e76.
[40] 中国医师协会儿科医师分会儿童耳鼻咽喉专业委员会. 儿童急性中耳炎诊疗——临床实践指南(2015年制定)[J].中国实用儿科杂志,2016,31(2):81-84.
[41] Lieberthal A S,Carroll A E,Chonmaitree T,et al. The diagnosis and management of acute otitis media[J]. Pediatrics,2013,131(3):e964-e999.
[42] 中华医学会儿科学分会消化学组,中华医学会儿科学分会感染学组,《中华儿科杂志》编辑委员会.儿童腹泻病诊断治疗原则的专家共识[J].中华儿科杂志,2009,47(8):634-636.
[43] Guarino A,Ashkenazi S,Gendrel D,et al. European Society for Pediatric Gastroenterology,Hepatology,and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe:update 2014[J]. J Pediatr Gastroenterol Nutr, 2014,59(1):132-152.
[44] 丁翔宇,刘艳辉,冯超,等.儿童急性胃肠炎指南的系统评价[J].中国循证医学杂志,2015,15(8):892-897.
[45] 马家明,都鹏飞.十年间儿童感染性腹泻细菌谱与耐药性变迁分析[J].中华疾病控制杂志,2015,19(5):481-487.
[46] Chow A W,Benninger M S,Brook I,et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults[J]. Clin Infect Dis,2012,54(8):e72-e112.
[47] 中华人民共和国卫生部.布鲁氏菌病诊疗指南(试行)[J].传染病信息,2012,25(6):323-324.
[48] World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children (second edition)[M]. 2014.
[49] 焦伟伟,孙琳,肖婧,等. 国家结核病规划指南-儿童结核病管理[J]. 第2版.中国循证儿科杂志,2016,12(1):65-74.
[50] Aldred K J,Kerns R J,Osheroff N. Mechanism of quinolone action and resistance[J]. Biochemistry,2014,53(10):1565-1574.
[51] Jacoby G A,Strahilevitz J,Hooper D C. Plasmid-mediated quinolone resistance[J]. Microbiol Spectr,2017,2(5):207-211.
[52] Rose L,Coulter M M,Chan S,et al. The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children[J]. Pediatr Infect Dis J,2014,33(6):e158-e161.
[53] Raidt L,Idelevich E A,Dübbers A,et al. Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade[J]. Pediatr Infect Dis J,2015,34(7):700-705.
[54] 李建华,姜晓云,毛惠珍,等.成人与儿童下呼吸道感染患者的病原菌分布及耐药性分析[J].中华医院感染学杂志,2015,25(20):4610-4612.
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
 
友情链接  
广东今日药学杂志社有限公司   地址:广州市东风东路753号东塔7楼702
电话:020-37886325       邮箱:jinriyaoxue@163.com
本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:400-921-9838
粤ICP备20054928号

粤公网安备 44010402002138号

您是第 165216 位访问者